MPSA Pathology Coordinating Center

描述（由申请人提供）： 良性前列腺增生（BPH）是美国男性最常见的前列腺增生性疾病。超过三分之二的50岁以上的男性患有某种程度的BPH。BPH的治疗每年接近50亿美元。前列腺肥大可能导致尿潴留，在某些情况下，肾功能损害。NIDDK赞助了一项名为“前列腺症状药物治疗（MTOPS）”的大型临床试验，该试验测试了两种药物（5 α-还原酶抑制剂非那肽和α-1肾上腺素能受体阻滞剂多沙唑嗪）单独或联合治疗这种疾病的能力。 作为本研究的一部分，每年抽取3000多名男性血清样本，约1000名男性在研究的0年、1年和5年进行前列腺活检。这些现在包括目前存放在我们机构的大量临床标本档案。这些标本的可用性为研究提供了一个宝贵的机会，以确定遗传和生物标志物，这将进一步加深我们对前列腺疾病的原因和进展以及对治疗的反应的理解。本申请的总体目标是建立病理学协调中心（PCC），以支持RFA-DK-02-017中所述的MTOPS前列腺样本分析（MPSA）联盟。作为对RFA的回应，病理学协调中心将在以下领域提供专业知识和资源：1）档案库管理和分发，作为MTOPS项目生成的所有血清和组织标本的储存库; 2）组织学，包括诊断解释、石蜡处理和切片、冷冻切片、常规光学显微镜、激光捕获显微切割、组织阵列，免疫组织化学和成像;和3）专业的样品制备，包括高质量的DNA纯化，用于蛋白质阵列和其他蛋白质组学应用的蛋白质提取，以及RNA的SMARTa cDNA扩增。我们的目的是提供最高质量的无偏倚患者样本，以满足各个研究团队的需求，无论他们的研究重点是遗传学，基因表达还是蛋白质组学。 我们相信，前列腺疾病生物标志物研究的质量，可靠性和适用性只能通过使用高质量的无偏倚患者标本来保证，这些标本以统一的方式处理，处理和解释，可以直接与临床信息和结果联系起来。

DESCRIPTION (provided by applicant): Benign prostatic hyperplasia (BPH) is the most common proliferative disease of the prostate in men in the United States. More than two thirds of men over age 50 have some degree of BPH. Treatment for BPH approaches $5 billion annually. Prostate enlargement may lead to urinary retention and, in some cases, renal impairment. The NIDDK has sponsored a large clinical trial entitled "Medical Therapy of Prostate Symptoms (MTOPS)" that tested the ability of two medications, the 5 a-reductase inhibitor finasteride and the alpha-1 adrenergic receptor blocker doxazosin, alone or in combination, to treat this disorder. As part of this study, over 3000 men had annual serum samples drawn and approximately 1000 men had prostate biopsies at 0, 1 and 5 years of the study. These now comprise a large archival collection of clinical specimens currently being housed at our institution. The availability of these specimens presents a valuable opportunity for research to identify genetic and biologic markers that will further our understanding of the causes and progression of prostatic diseases and responses to therapy. The overall aim of this application is to establish a Pathology Coordinating Center (PCC) in support of the MTOPS Prostate Samples Analysis (MPSA) Consortium as described in RFA-DK-02-017. In response to the RFA, the Pathology Coordinating Center will provide expertise and resources in the areas of: 1) Archival Repository Management and Distribution, acting as a repository for all the serum and tissue specimens generated by the MTOPS project; 2) Histopathology, including diagnostic interpretation, paraffin processing and microtomy, cryomicrotomy, conventional light microscopy, laser capture microdissection, tissue arrays, immunohistochemistry, and imaging; and 3) Specialized Sample Preparation including high-quality DNA purifications, protein extractions for protein arrays and other proteomic applications, and SMARTa cDNA amplification of RNA. Our intent is to provide the highest quality non-biased patient samples prepared to meet the needs of individual research teams whether their studies focus on genetics, gene expression, or proteomics. It is our belief that the quality, reliability and applicability of biomarker research in prostatic diseases can only be guaranteed through the use of high quality non-biased patient specimens that have been handled, processed and interpreted in a uniform manner that can be directly linked to clinical information and outcome.